Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug-Eluting Stents Prevent
June 19, 2006
- Korosho to Work Out New Industry Vision
June 19, 2006
- MEDICAL DEVICE NEWS IN BRIEF
June 19, 2006
- Consent Not Obtained for Insulin
June 19, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 19, 2006
- SURVEY 4 articles
June 19, 2006
- SELF-MEDICATION NEWS IN BRIEF
June 19, 2006
- Abilify to Accelerate Otsuka's
June 19, 2006
- MIYARISAN Licenses
June 19, 2006
- Diet Approves PAL Amendment
June 19, 2006
- Respiratory Drugs to Be
June 19, 2006
- NHI Price Listing Announced for
June 19, 2006
- BUSINESS NEWS IN BRIEF
June 19, 2006
- PMDA Identifies Problems to Improve Its Services
June 19, 2006
- Torrent of India Starts Business in Japan
June 19, 2006
- REGULATORY NEWS IN BRIEF
June 19, 2006
- JGPMA Drafting Model for GE Drug
June 19, 2006
- Eliminate Provisional Delivery
June 12, 2006
- Subjects' Protection Key to
June 12, 2006
- Dr Amamoto of NEUES
June 12, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…